CN219721520U - Artificial in-vitro pancreas based on insulin and glucagon - Google Patents
Artificial in-vitro pancreas based on insulin and glucagon Download PDFInfo
- Publication number
- CN219721520U CN219721520U CN202320986728.0U CN202320986728U CN219721520U CN 219721520 U CN219721520 U CN 219721520U CN 202320986728 U CN202320986728 U CN 202320986728U CN 219721520 U CN219721520 U CN 219721520U
- Authority
- CN
- China
- Prior art keywords
- glucagon
- module
- insulin
- glucose oxidase
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 102000004877 Insulin Human genes 0.000 title claims abstract description 49
- 108090001061 Insulin Proteins 0.000 title claims abstract description 49
- 229940125396 insulin Drugs 0.000 title claims abstract description 49
- 102000051325 Glucagon Human genes 0.000 title claims abstract description 42
- 108060003199 Glucagon Proteins 0.000 title claims abstract description 42
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title claims abstract description 42
- 229960004666 glucagon Drugs 0.000 title claims abstract description 42
- 210000000496 pancreas Anatomy 0.000 title claims abstract description 20
- 238000000338 in vitro Methods 0.000 title claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 53
- 239000007924 injection Substances 0.000 claims abstract description 53
- 239000008280 blood Substances 0.000 claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 50
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 39
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 39
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 39
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 39
- 239000000523 sample Substances 0.000 claims abstract description 27
- 230000000149 penetrating effect Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 81
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052744 lithium Inorganic materials 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
- 239000008103 glucose Substances 0.000 abstract description 17
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 229940090044 injection Drugs 0.000 description 38
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 102000016261 Long-Acting Insulin Human genes 0.000 description 2
- 108010092217 Long-Acting Insulin Proteins 0.000 description 2
- 229940100066 Long-acting insulin Drugs 0.000 description 2
- 108010026951 Short-Acting Insulin Proteins 0.000 description 2
- 229940123958 Short-acting insulin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940048956 glucagon injection Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940127560 insulin pen Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 206010040576 Shock hypoglycaemic Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- External Artificial Organs (AREA)
Abstract
The utility model discloses an artificial in-vitro pancreas based on insulin and glucagon, comprising: the device comprises an indwelling needle, an insulin injection module, an injection glucagon, a processing module, an electric tube module and a glucose oxidase probe module, wherein the glucose oxidase probe module comprises a blood storage tank, glucose oxidase paper, a blood return capillary, a supporting plate, a glucose oxidase probe and a measuring electrode; the blood storage groove is arranged on the supporting plate and is provided with a contact groove penetrating through the side surface of the supporting plate; the glucose oxidase probe is arranged on the supporting plate, one end of the glucose oxidase probe is abutted against the contact groove, glucose oxidase paper is arranged at one end of the glucose oxidase probe, which is close to the contact groove, and a measuring electrode is connected with the glucose oxidase paper; the blood storage tank is provided with a blood return capillary. The utility model can automatically detect the blood sugar concentration in blood, judge according to the blood sugar concentration, and automatically inject insulin or glucagon. Thereby stabilizing blood glucose levels in the body.
Description
Technical Field
The utility model relates to the technical field of medical equipment, in particular to an artificial in-vitro pancreas based on insulin and glucagon.
Background
Diabetes is currently largely classified into type one diabetes (insulin-dependent diabetes mellitus) and type two diabetes (non-insulin-dependent diabetes mellitus). For type II diabetics, the light person is generally treated with oral medications, such as oral metformin and the like. Heavier patients are generally treated with insulin pens. According to the different medicines used by insulin pens, the insulin pen is matched with different physique of patients and is divided into long-acting insulin, short-acting insulin and mixed insulin. Different drugs have different times of insulin action to meet the treatment of patients with different foods and different conditions. Because of the variety of insulin and the complexity of the patient's own illness and the relationship with the patient's diet, in the technology of strengthening treatment of diabetes in general, the patient must be strictly required to control the diet, and the meal is timed and quantitative, and the variety of the meal cannot be changed too much. Which would otherwise lead to a drastic change in the blood glucose of the patient and thus present a hazard.
In addition, when the insulin pen is used for treatment, the patient needs to inject the medicine for 4 times a day in general, namely, short-acting insulin is respectively injected once before three meals in the morning, in the middle and at night, and then the patient needs to inject long-acting insulin once before sleeping. Meanwhile, blood glucose is measured by adopting fingertip blood before three meals. Blood glucose was also measured 2 hours for three meals, and one blood glucose was also measured before sleeping. Thus calculated, the patient measured blood glucose and injected insulin for a total of 11 needles a day. This is conceivable to be very painful for the patient.
In addition, there is an insulin pump on the market at present, which achieves the purpose of making the blood sugar of the patient more stable through a mixed injection mode of basal rate injection and preprandial large dose injection. However, this device has the fatal disadvantage that it causes fatal hypoglycemia to occur when the patient moves vigorously once, or does not eat a prescribed amount of food within a prescribed period of time. Because the traditional insulin pump can only inject insulin simply, the blood sugar can be reduced in one direction only. Once the blood glucose is too low, it is no longer possible to raise the blood glucose. While hyperglycemia leads to chronic deterioration of the patient, hypoglycemia is likely to cause the patient to lose consciousness instantaneously, and even cause death. The risk of hypoglycemia is far higher than that of hyperglycemia. Whereas conventional insulin pumps do not.
And the control operation and display content of the traditional insulin pump are basically on the pump body. Moreover, since the conventional insulin pump adopts an assembly mode that the injection needle is closely connected with the pump body, the injection tube is not separated from the pump body, and bacteria can enter a connecting position due to forced separation. Patient handling and viewing is inconvenient. In some public places, some patients cannot at all do the unhook to adjust the settings above the insulin pump. Thereby bringing great inconvenience to the patient.
Whatever the above treatment, all preconditions are based on the patient's strict diet control. Without strict timing and quantitative diet and planning, light people can lead to large blood glucose fluctuations, and heavy people can lead to hypoglycaemic shock, even life threatening. But also strict exercise planning must be specified, otherwise a risk of hypoglycemia is created.
Disclosure of Invention
Aiming at the problems in the prior art, the utility model provides an artificial external pancreas based on insulin and glucagon, which has the functions of almost completely replacing the original biological pancreas of a human body, realizes the mode of simulating the biological pancreas of the human body, secretes the insulin and glucagon, fundamentally increases the effective means for preventing hypoglycemia and increases the injection of glucagon, thereby realizing accurate and bidirectional control of the glucose content level in the blood of the human body and achieving the effect of treating diabetes.
The utility model provides an artificial in-vitro pancreas based on insulin and glucagon, which adopts the following technical scheme:
an artificial in vitro pancreas based on insulin and glucagon comprising:
the retaining needle is provided with two injection joints;
the insulin injection module is connected with one of the injection joints and is used for injecting insulin;
a glucagon module connected to another injection connector for injecting glucagon;
the glucose oxidase probe module comprises a blood storage tank, glucose oxidase paper, a blood return capillary, a supporting plate, a glucose oxidase probe and a measuring electrode; the blood storage groove is arranged on the supporting plate and is provided with a contact groove penetrating through the side surface of the supporting plate; the glucose oxidase probe is arranged on the supporting plate, one end of the glucose oxidase probe is abutted against the contact groove, glucose oxidase paper is arranged at one end of the glucose oxidase probe, which is close to the contact groove, and a measuring electrode is connected with the glucose oxidase paper; a blood return capillary is arranged on the blood storage tank;
the processing module receives signals of the measuring electrode to drive the insulin injection module and the glucagon module to work;
and the power supply module is used for supplying electric energy to the processing module and the measuring electrode.
Preferably, the insulin injection module and the glucagon module each comprise: the device comprises an injection chuck, a medicine storage device, a medicine pushing plug, a medicine feeding nut, a medicine feeding screw rod and a driving device; the injection chuck is used for communicating the medicine storage device and the injection joint, one end of the medicine storage device, which is far away from the injection joint, is provided with a medicine pushing plug for medicine administration, the medicine pushing plug is connected with a medicine feeding nut, and the medicine feeding nut is in threaded connection with a medicine feeding screw rod; the driving device drives the medicine feeding screw rod to rotate and drive the medicine feeding nut in threaded connection with the medicine feeding screw rod to move so as to push the medicine pushing plug to feed medicine; the power module provides power for the driving device.
Preferably, one end of the medicine feeding screw far away from the medicine feeding nut is provided with a medicine feeding gear, an output shaft of the driving device is connected with a driving gear, the driving gear is in meshed connection with a reversing gear, and the reversing gear is meshed with the medicine feeding gear.
Preferably, the insulin injection module, the glucagon module, the glucose oxidase probe module, the processing module and the power supply module are all arranged in the fixed shell; the medicine feeding nut is provided with a guide block, the fixed shell is provided with a guide groove, and the guide block is inserted into the guide groove.
Preferably, the driving device is a stepper motor.
Preferably, the battery module is a rechargeable lithium battery, and a data line charging connector is connected with the rechargeable lithium battery.
Preferably, the indwelling needle comprises a sterile patch, a needle head, a fixed handle, a catheter and two injection joints; one end of the catheter is connected with the needle head, and the other end of the catheter is connected with two injection joints; the needle head is connected with the sterile application through a fixed handle.
Preferably, the artificial exosomatic pancreas further comprises a controller, and the controller is connected with the processor through Bluetooth.
In summary, the present utility model includes at least one of the following beneficial technical effects:
1. the blood glucose concentration in blood can be automatically detected, judged according to the blood glucose concentration, and insulin or glucagon can be automatically injected. Thereby stabilizing blood glucose levels in the body;
2. the device for injecting insulin and glucagon and the device for detecting blood glucose concentration are introduced into human body by adopting one venous indwelling needle, so that the pain of patients is reduced.
Drawings
FIG. 1 is a schematic diagram of the structure of the present utility model;
FIG. 2 is a schematic illustration of the construction of a sterile applicator of the present utility model;
FIG. 3 is a schematic diagram of a controller according to the present utility model;
FIG. 4 is a schematic diagram of the structure of a glucose oxidase probe module of the present utility model.
Reference numerals illustrate: 1. a retention needle; 101. an injection joint; 102. sterile application; 103. a needle; 104. a fixed handle; 105. a conduit; 2. an insulin injection module; 3. a glucagon module; 4. a glucose oxidase probe module; 401. a blood storage tank; 402. glucose oxidase paper; 403. a blood return capillary; 404. a support plate; 405. a glucose oxidase probe; 406. a measuring electrode; 407. a contact groove; 5. a processing module; 6. an injection chuck; 7. a drug reservoir; 8. pushing the medicine plug; 9. a medicine feeding nut; 10. a medicine feeding screw rod; 11. a driving device; 12. a medicine feeding gear; 13. a drive gear; 14. reversing the gear; 15. a fixed housing; 16. a guide block; 17. a guide groove; 18. a data line charging connector; 19. a controller; 20. and a power supply module.
Detailed Description
The utility model is described in further detail below with reference to fig. 1-4.
An artificial in vitro pancreas based on insulin and glucagon of the present embodiment, referring to fig. 1, 2, 4, comprises:
the retaining needle 1 is provided with two injection joints 101;
an insulin injection module 2 connected to one of the injection joints 101 for injecting insulin;
a glucagon module 3 connected to the other injection joint 101 for injecting glucagon;
a glucose oxidase probe 405 module 4 comprising a blood reservoir 401, glucose oxidase paper 402, a blood return capillary 403, a support plate 404, a glucose oxidase probe 405, a measurement electrode 406; the blood storage groove 401 is arranged on the supporting plate 404, and a contact groove 407 is arranged through the side surface of the blood storage groove; the glucose oxidase probe 405 is arranged on the supporting plate 404, one end of the glucose oxidase probe is abutted against the contact slot 407, one end of the glucose oxidase probe 405, which is close to the contact slot 407, is provided with glucose oxidase paper 402, and a measuring electrode 406 is connected with the oxidase paper; a blood return capillary 403 is arranged on the blood storage tank 401;
the processing module 5 receives the signal of the measuring electrode 406 to drive the insulin injection module 2 and the glucagon module 3 to work;
the power module 20 supplies power to the processing module 5 and the measuring electrode 406.
By adopting the scheme, the blood glucose concentration of the artificial external pancreas wearer can be automatically detected, and insulin or glucagon can be automatically injected, so that the blood glucose level in the human body is stabilized. The device for injecting insulin and glucagon and the device for detecting blood glucose concentration are introduced into human body by adopting one venous indwelling needle 1, so that the pain of patients is reduced.
In one embodiment, referring to fig. 1, the insulin injection module 2 and the glucagon module 3 each comprise: the injection clamp 6, the medicine storage device 7, the medicine pushing plug 8, the medicine feeding nut 9, the medicine feeding screw 10 and the driving device 11; the injection chuck 6 is used for communicating the medicine storage device 7 and the injection joint 101, one end of the medicine storage device 7, which is far away from the injection joint 101, is provided with a medicine pushing plug 8 for medicine administration, the medicine pushing plug 8 is connected with a medicine feeding nut 9, and the medicine feeding nut 9 is in threaded connection with a medicine feeding screw rod 10; the driving device 11 drives the medicine feeding screw rod 10 to rotate so as to drive the medicine feeding nut 9 in threaded connection with the medicine feeding screw rod to move, thereby pushing the medicine pushing plug 8 to feed medicine; the power module 20 supplies power to the driving device 11.
So set up, processing module 5 drives into medicine screw rod 10 through controlling drive arrangement 11 and rotates for thereby with its threaded connection's medicine feeding nut 9 displacement promotes the function of pushing away medicine stopper 8 and realizing dosing.
In one embodiment, referring to the drawings, one end of the medicine feeding screw 10 away from the medicine feeding nut 9 is provided with a medicine feeding gear 12, an output shaft of the driving device 11 is connected with a driving gear 13, the driving gear 13 is in meshed connection with a reversing gear 14, and the reversing gear 14 is meshed with the medicine feeding gear 12.
In one embodiment, referring to fig. 1, the insulin injection module 2, the glucagon module 3, the glucose oxidase probe 405 module 4, the processing module 5, and the power module 20 are all mounted within a stationary housing 15; the medicine feeding nut 9 is provided with a guide block 16, the fixed shell 15 is provided with a guide groove 17, and the guide block 16 is inserted into the guide groove 17.
By the arrangement, under the action of the guide groove 17 and the guide block 16, the medicine feeding nut 9 moves along the direction of the guide groove 17, so that the medicine feeding purpose is achieved.
In one embodiment, referring to fig. 1, the driving device 11 is a stepper motor. The stepper motor is selected to control the stroke of the motor well, so that accurate drug delivery is realized.
In one embodiment, referring to fig. 1, the battery module 20 is a rechargeable lithium battery, and the data line charging connector 18 is connected to the rechargeable lithium battery.
In one embodiment, referring to fig. 2, the indwelling needle 1 comprises a sterile applicator 102, a needle 103, a fixing handle 104, a catheter 105 and two injection connectors 101; one end of the catheter 105 is connected with the needle 103, and the other end is connected with the two injection joints 101; the needle 103 is connected to the sterile application 102 by a fixed handle 104.
In one embodiment, referring to fig. 3, the artificial exocrine pancreas further comprises a controller 19, the controller 19 being connected to the processor via bluetooth. The operation of the processing module 5 can be controlled more conveniently by the controller 19.
The working principle of the utility model is as follows: 1. the insulin injection and the glucagon injection in the medicine storage device 7 both contain heparin sodium solution, the blood coagulation degree is calculated according to the current of the back suction motor when blood is back sucked, when the blood is about to generate a coagulation phenomenon, the insulin and the glucagon are injected in equal proportion, and the actions of the insulin and the glucagon are mutually counteracted, so that the injection is equivalent to the injection of heparin sodium solution only, and the venous indwelling needle 1 is prevented from coagulating;
2. the processing module 5 controls the stepping motor to work according to the detected blood sugar concentration information so as to realize insulin and glucagon injection.
The embodiments of the present utility model are all preferred embodiments of the present utility model, and are not intended to limit the scope of the present utility model in this way, therefore: all equivalent changes in structure, shape and principle of the utility model should be covered in the scope of protection of the utility model.
Claims (8)
1. An artificial in vitro pancreas based on insulin and glucagon comprising:
the retaining needle is provided with two injection joints;
the insulin injection module is connected with one of the injection joints and is used for injecting insulin;
a glucagon module connected to another injection connector for injecting glucagon;
the glucose oxidase probe module comprises a blood storage tank, glucose oxidase paper, a blood return capillary, a supporting plate, a glucose oxidase probe and a measuring electrode; the blood storage groove is arranged on the supporting plate and is provided with a contact groove penetrating through the side surface of the supporting plate; the glucose oxidase probe is arranged on the supporting plate, one end of the glucose oxidase probe is abutted against the contact groove, glucose oxidase paper is arranged at one end of the glucose oxidase probe, which is close to the contact groove, and a measuring electrode is connected with the glucose oxidase paper; a blood return capillary is arranged on the blood storage tank;
the processing module receives signals of the measuring electrode to drive the insulin injection module and the glucagon module to work;
and the power supply module is used for supplying electric energy to the processing module and the measuring electrode.
2. An artificial in vitro insulin-and glucagon-based pancreas according to claim 1, wherein: the insulin injection module and the glucagon module each comprise: the device comprises an injection chuck, a medicine storage device, a medicine pushing plug, a medicine feeding nut, a medicine feeding screw rod and a driving device; the injection chuck is used for communicating the medicine storage device and the injection joint, one end of the medicine storage device, which is far away from the injection joint, is provided with a medicine pushing plug for medicine administration, the medicine pushing plug is connected with a medicine feeding nut, and the medicine feeding nut is in threaded connection with a medicine feeding screw rod; the driving device drives the medicine feeding screw rod to rotate and drive the medicine feeding nut in threaded connection with the medicine feeding screw rod to move so as to push the medicine pushing plug to feed medicine; the power module provides power for the driving device.
3. An artificial in vitro insulin-and glucagon-based pancreas according to claim 2, wherein: the medicine feeding screw is characterized in that one end, far away from the medicine feeding nut, of the medicine feeding screw is provided with a medicine feeding gear, an output shaft of the driving device is connected with a driving gear, the driving gear is connected with a reversing gear in a meshed mode, and the reversing gear is meshed with the medicine feeding gear.
4. An artificial in vitro insulin-and glucagon-based pancreas according to claim 2, wherein: the insulin injection module, the glucagon module, the glucose oxidase probe module, the processing module and the power supply module are all arranged in the fixed shell; the medicine feeding nut is provided with a guide block, the fixed shell is provided with a guide groove, and the guide block is inserted into the guide groove.
5. An artificial in vitro insulin-and glucagon-based pancreas according to any of the claims 2-4, wherein: the driving device is a stepping motor.
6. An artificial in vitro insulin-and glucagon-based pancreas according to any of the claims 1-4, wherein: the power module is a rechargeable lithium battery, and a data line charging connector is connected with the rechargeable lithium battery.
7. An artificial in vitro insulin-and glucagon-based pancreas according to claim 1, wherein: the retaining needle comprises a sterile application, a needle head, a fixed handle, a catheter and two injection joints; one end of the catheter is connected with the needle head, and the other end of the catheter is connected with two injection joints; the needle head is connected with the sterile application through a fixed handle.
8. An artificial in vitro insulin-and glucagon-based pancreas according to any of the claims 1-4 or 7, characterized in that: the artificial exopancreas further comprises a controller, and the controller is connected with the processor through Bluetooth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202320986728.0U CN219721520U (en) | 2023-04-27 | 2023-04-27 | Artificial in-vitro pancreas based on insulin and glucagon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202320986728.0U CN219721520U (en) | 2023-04-27 | 2023-04-27 | Artificial in-vitro pancreas based on insulin and glucagon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN219721520U true CN219721520U (en) | 2023-09-22 |
Family
ID=88059982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202320986728.0U Active CN219721520U (en) | 2023-04-27 | 2023-04-27 | Artificial in-vitro pancreas based on insulin and glucagon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN219721520U (en) |
-
2023
- 2023-04-27 CN CN202320986728.0U patent/CN219721520U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Soeldner | Treatment of diabetes mellitus by devices | |
| US10238795B2 (en) | Device for drug delivery | |
| ES2785056T3 (en) | A device for drug delivery | |
| Reeves et al. | Glycemic control in insulin-dependent diabetes mellitus: comparison of outpatient intensified conventional therapy with continuous subcutaneous insulin infusion | |
| CA2665275A1 (en) | Optical determination of the position of the stopper in glass ampoules | |
| CN102836481A (en) | Novel insulin pump | |
| CN104436362B (en) | A kind of infusion pump | |
| KR100723808B1 (en) | Automatic controlled insulin pump mounted with injection sensor | |
| CN219721520U (en) | Artificial in-vitro pancreas based on insulin and glucagon | |
| Home et al. | Insulin treatment: a decade of change | |
| CN108543155A (en) | A kind of repeatable dressing insulin pump | |
| Plodkowski et al. | The state of insulin pump therapy: 2002 | |
| Pickup et al. | Technology and the diabetic patient | |
| CN204379897U (en) | A kind of infusion pump | |
| CN204033919U (en) | A kind of medical intravenous insulin pump | |
| Clement et al. | Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: A case report | |
| US20160106932A1 (en) | Device and method for hindering formation of lipohypertrophy | |
| JP4177659B2 (en) | Device for injecting insulin | |
| CN209827916U (en) | Retractable insulin pump catheter | |
| Franetzki | Drug delivery by program or sensor controlled infusion devices | |
| Levy-Marchal et al. | Overnight metabolic control with pulsed intermittent versus continuous subcutaneous insulin infusion | |
| CN116492534A (en) | Artificial in-vitro pancreas based on insulin and glucagon | |
| CN205867230U (en) | Hypodermic structure | |
| Pfeiffer et al. | Use of artificial pancreas and portable insulin infusion pumps in diabetes therapy: past, present, and future | |
| CN112370607B (en) | Insulin pump therapeutic instrument |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |